ArticleMedicine2026
Dietary advanced glycation end products intake and osteoporosis risk in adults with type 2 diabetes mellitus.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced glycation end products (AGEs) derived from dietary sources may aggravate metabolic inflammation and impair bone turnover in patients with type 2 diabetes mellitus (T2DM); however, clinical evidence linking dietary AGEs exposure to osteoporosis (OS) in T2DM remains limited. In this retrospective cohort study, 200 adults with T2DM treated at a tertiary hospital between January 2020 and December 2022 were included. Dietary AGEs intake at baseline was quantified using a simplified food frequency questionnaire complemented by a 3-day dietary record and categorized as high (≥75th percentile), moderate (50th-<75th percentile), or low (<50th percentile). Osteoporosis and osteopenia were defined by dual-energy X-ray absorptiometry T-scores. Inflammatory markers (procalcitonin [PCT], interleukin-6 [IL-6], and C-reactive protein [CRP]) were assessed at baseline and at each patient's last available follow-up. Logistic regression was performed to identify factors independently associated with OS, and receiver operating characteristic (ROC) curves evaluated predictive performance. The incidence of OS differed across dietary AGEs categories (45.0% high, 23.9% moderate, 18.6% low; P = .013). At the last available follow-up, the low-intake group exhibited lower PCT, IL-6, and CRP levels than the high- and moderate-intake groups (all P < .05). Multivariable analysis identified PCT, β-CTX, P1NP, and dietary AGEs intake as independent factors associated with OS (all P < .05). Dietary AGEs intake showed acceptable discrimination for OS (AUC = 0.797). Higher dietary AGEs intake was associated with a greater likelihood of osteoporosis in adults with T2DM and may contribute through inflammation-related and bone turnover-related pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.